Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)
NCT05407324 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)
- Lead sponsor
- Corcept Therapeutics
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- November 15, 2022
- Completion date
- November 30, 2027
- Enrollment
- 279 (estimated)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.